Sophia, catalyst will come from liquid version of Amitiza for elderly over 65 years old and also pediatric version for children between 6 months to 6 (based on cash_is_king post) and and also for ages 7 to 17 first.
Ironwood made a lot of noise for Linzess but it failed in Japan to get approval or even pass phase 2. Linzess efficacy is not as strong as Amitiza. We saw 6% Amitiza growth in Q4 with 341k prescriptions the highest ever in a quarter. So, forget about losing market shares. After all, Amitiza hs more indications.
Dr Ueno was not a 12 years old to sell his 25 m shares at the market. He is not selling lemonade drink at his door step. All he needed to do was to call JPM and asked them to cash in the shares at $15 or higher and JPM probably responded to wait since you can get $25 or higher per share.
Cantor deal was probably work of an inexperienced accountant in the company.
Rescula launch was work of inexperienced sale and marketing department that never done it before.
So, the company leaned that dr Ueno cannot have different hats and competes in this market.
The right step was to hire a new CEO with right experience and put the board under different leadership.
I see more changes in the way and SCMP finally be a public company that attract investors.
Martin, if SCMP did not hire a new CEO then that was hinting business as usual.
However, somebody or board saw the weaknesses especially Rescula sale disappointment. Although SCMP was doing excellent in R&D but marketing, sale and commercializing of new products were very weak. SCMP needed somebody with experience and knowledge in sale and marketing while understanding the drug development and new CEO was an excellent choice. I think, he will build a strong marketing and sale group since SCMP will have more products to handle here in US in future. Also, it may cancel takada contract and handles Amitiza sale itself. Anyway, this is an exciting time and finally things are going in right direction. In addition, new CEO will bring his own trusted people and we may see more hires and changes in future. Yes, some of the people should be changed. If Dr Ueno is out then there is no problem to change others.
I look at this as new company with new blood that already lined up many successes and ready to continue and benefit from current situation.
Yes, there is high probability that new CEO will be present at ROTH CC and I think he is prepared to show his ability. He has to start from somewhere and this is the time and place since this CC was added recently and probably new CEO requested the action.
I want to thank people who have been contributing here and those who made us a better investors. Of course Mike and Post as the original and few more recently come to mind. A few are missing with their knowledges. I went back and read some of the old posts when HZNP was at low $6. I also look at some of the predictions from that time and really saw the numbers that med_investor put and price he predicted is obvious now.
I am lucky that he started to post at SCMP board and just the info and knowledge he puts there worth reading.
I am over 100% up here, enjoyed divi from POZN and diversified some to SCMP and I am hoping it acts like HZNP, especially now that we a few knowledgeable posters over there.
I don't think you get it, martin.
Let me see if you understand the financial world so let me ask this question:
Why MSFT or AAPL with tons of money issue convertible and then buyback their shares? If you figure out this then you understand my point. I won't go thru other issue now.
I hope new CEO realizes that he needs to do some serious works and the first thing in his list should be creating “LIQUIDITY”.
1- Make the company more open so investor can trust it.
2- Bring more institutional investors.
3- Split the shares at least 1 to 3 to create more liquidity.
4- Issue a convertible bond and use the cash to purchase the shares and expand the company.
5- Get better deal for new drugs, increase sale...
Will it continue to drop? May be and I wait a little more for taking any action. I may switch some of the profit to other stocks. SCMP may be a good buy at current levels.
any acquisition needs money and money comes from refinancing like issuing a new convertible bond. this is good price for a new bond. I am afraid that previous bond holders to convert before HZ get a chance to issue a new one.
Humira from old Abbott and now ABBV. It did not matter who was selling Humira since it was a blockbuster drug and the income and sale would be the same.
The headline is positive but the article is very negative.
Yah, Mr. Greenleaf started his move and a CC will be on March 12. There may be some update too.
Thanks for introducing ARWR. I may consider. I am selling my POZN and I needed another good done.
Analysts put the target at $45 since their drug can be a huge one.
With the same token, I am adding more of SCMP since SCMP AMITIZA has OIC indication plus other indications and OIC indication is growing at 31% month over month in average. Good positive income and a huge pipeline with a few in phase 3 that will be approved late this year or next year.
Those are my holdings.
I may switch money among them but I see HZNP to start to slow down a bit while POZN and SCMP may run in near future. One thing I am puzzled is why SCMP with very low PE, good balance sheet, Low float and very strong pipeline cannot go above $10.
HPNP runs hot but still negative earnings.
POZN runs slow but high positive in near future
SCMP is volatile but it has been positive in past, now and in future with strong pipeline and 2 approved drugs.
I do not think if Dr Ueno wants to damage his shares price, the company or shareholders. The best solution would be sale of the company at a reasonable price which may take a year or so. New CEO will benefit too.
A scientist will be a scientist for good and joy of the work and accomplishment never can be replaced with money. That is why Dr Ueno is more excited about the drugs he developed but not the money he gets from his hard work. By the same token, he will not disappoint the shareholders who supported the company.
I have more shares of POZN than HZNP. I also have SCMP. Both POZN and SCMP have low float and positive income and they rock in future.
The volume is strange for a stock with only 185 m shares. If the outstanding shares were above 1 billion then it was possible to have this kind of volume daily without any news.
However, the float will decrease as soon as some institutions step in and tomorrow is the time for institutions to shop around for potential stocks. Having FDA and EU approvals for Iclusig, ARIA is one of those stocks with good potential. I think ARIA possibly goes green tomorrow.